Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

BioCryst Lead Compound Demonstrates Efficacy in the Treatment of Psoriasis and Severe Form of Skin Cancer in Phase II Clinical Trials.


BIRMINGHAM, AL--(HealthWire)--February 6, 1995--BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that a topical formulation of its lead compound, BCX-34, showed evidence of efficacy and safety in two separate Phase II clinical studies for the treatment of two serious skin diseases, psoriasis and cutaneous T-cell lymphoma Cutaneous T-Cell Lymphoma Definition

Cutaneous T-cell lymphoma (CTCL) is a malignancy of the T-helper (CD4+) cells of the immune system.
Description
 (CTCL CTCL Cutaneous T Cell Lymphoma ).

Psoriasis is a chronic disease, affecting approximately 5 million people in the U.S., and is characterized by development of thick, scaly scal·y
adj.
1. Covered or partially covered with scales.

2. Shedding scales or flakes; flaking.



scaly

skin condition characterized by scales; scalelike.
, itchy patches or welt-covered areas of skin. CTCL is a form of cancer in which thick, scaly lesions on the skin progress to ulcers and tumors of the lymph nodes Lymph nodes
Small, bean-shaped masses of tissue scattered along the lymphatic system that act as filters and immune monitors, removing fluids, bacteria, or cancer cells that travel through the lymph system.
 and internal organs. There are approximately 5,000 patients in the U.S. affected by CTCL. Therapies currently available for both of these diseases are ineffective or have undesirable side effects Side effects

Effects of a proposed project on other parts of the firm.
.

The Phase II clinical trials, involving 40 patients with psoriasis and 30 patients with CTCL, evaluated the effectiveness of topical formulations containing concentrations of BCX-34 ranging from 5 percent to 0.1 percent. A severity scoring system of relevant symptoms ("global score") resulted in a greater than 50 percent improvement of lesions after a six-week treatment course, even at the lowest doses of drug. The global score is a summary evaluation of thickness, inflammation, scaling and patient response. The global scores for both trials were statistically significant compared to the effects associated with application of the base cream alone to comparable lesions in the same patients. These Phase II trial outcomes are not necessarily predictive of the results of future trials for these indications.

"Both of these trials provided encouraging results for BCX-34," said William J. Cook, M.D., Ph.D., vice president of Medical Affairs at BioCryst. "Responses were observed in both studies after only one week of treatment. We are particularly excited about the marked clearing of CTCL lesions within six weeks of treatment: three test lesions cleared completely and there was an overall average reduction of 55 percent in lesion area. We look forward to our next stage of clinical trials, which are designed to establish optimal dosing and treatment regimens."

"In addition to the positive efficacy data, these studies showed no significant irritative ir·ri·ta·tive  
adj.
Involving irritation.

Adj. 1. irritative - (used of physical stimuli) serving to stimulate or excite; "an irritative agent"
irritating
 or other side effects associated with continuous use of BCX-34 Dermal dermal /der·mal/ (der´mal) pertaining to the dermis or to the skin.

der·mal or der·mic
adj.
Of or relating to the skin or dermis.
 Cream. We believe that this compound's strong safety profile will prove beneficial when testing the drug in extended usage trials," said Charles E. Bugg, Ph.D. chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  of BioCryst. "We are also in the process of gathering preliminary safety and efficacy data with oral and intravenous formulations of BCX-34 for CTCL and psoriasis, as well as our other targeted indications."

BioCryst Pharmaceuticals, Inc. designs and develops novel small-molecule pharmaceuticals using structure-based drug design, an approach to drug discovery that integrates advanced biology, biophysics biophysics, application of various methods and principles of physical science to the study of biological problems. In physiological biophysics physical mechanisms have been used to explain such biological processes as the transmission of nerve impulses, the muscle  and medicinal chemistry. BioCryst is currently applying this approach to develop drug treatments for autoimmune and cardiovascular disorders and infectious diseases.

CONTACT: BioCryst Pharmaceuticals, Inc.

John L. Higgins

Director, Corporate Development

205/444-4600

or

Burns McClellan, Inc.

John M. Nugent (Investor inquiries)

James W. Heins (Media inquiries)

212/505-1919
COPYRIGHT 1995 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1995, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 6, 1995
Words:503
Previous Article:Metallgesellschaft AG sues former executives.
Next Article:REPEATING Foster Wheeler to build Thai Polystyrene plant.
Topics:



Related Articles
QUADRA LOGIC TECHNOLOGIES -- TOPICAL BPD AND LIGHT-EMITTING DIODES TO BE USED IN NEW PSORIASIS TRIAL.
BIOCRYST REPORTS FIRST QUARTER FINANCIAL RESULTS.
Targretin(R) Capsules Show Positive Results in Moderate to Severe Plaque Psoriasis; Targretin Capsules Also Effective in Treating All Stages Of CTCL.
New Data Confirming Effective and Well-Tolerated Dose for ONTAK in Patients With Severe Psoriasis Presented at the Society for Investigative...
ANGIOTECH ANNOUNCES PSORIASIS GEL DETERMINED TO BE SAFE.
Corixa, Medicis and Genesis Announce Phase II Trial Evidence of Clinical Benefit and Safety At 15-Microgram Dose.
Phase III Clinical Trials of Xanelim Humanized Monoclonal Antibody for Moderate-to-Severe Psoriasis Show Preliminary Positive Results.
ANTISENSE TO INITIATE "PROOF OF CONCEPT" STUDY OF ATL1101.
UCB INITIATES ADDITIONAL SHORT-TERM CLINICAL STUDY OF CIMZIA.
TOPOTARGET UNVEILS AVUGANE PHASE II TRIAL FOR ACNE VULGARIS.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles